Steven Moss
29Patents
3h-index
28Co-inventors
63Inventor score
Filing activity: Jul 16, 2003 → Sep 14, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9119853B2 | Sanglifehrin based compounds | Chemistry; Metallurgy | 7 | Active |
| US7648996B2 | 39-desmethoxy derivatives of rapamycin | Human Necessities | 7 | Active |
| US8008318B2 | 39-desmethoxy derivatives of rapamycin | Human Necessities | 6 | Active |
| US7390895B2 | Production of polyketides and other natural products | Chemistry; Metallurgy | 3 | Active |
| US7300942B2 | Production of polyketides and other natural products | Chemistry; Metallurgy | 3 | Expired |
| US7645768B2 | Production of polyketides and other natural products | Chemistry; Metallurgy | 2 | Active |
| US7560252B2 | Borrelidin-producing polyketide synthase and its use | Emerging Cross-Sectional Technologies | 2 | Expired |
| US10307389B2 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation | Human Necessities | 2 | Active |
| US11565998B2 | Succinate prodrug, compositions containing the succinate prodrug and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US9040259B2 | Production of polyketides and other natural products | Chemistry; Metallurgy | 1 | Active |
| US9505773B2 | Rapamycin analogues and their pharmaceutical use | Emerging Cross-Sectional Technologies | 0 | Active |
| US9382266B2 | Rapamycin analogue | Chemistry; Metallurgy | 0 | Active |
| US9090657B2 | Compound and methods for its production | Chemistry; Metallurgy | 0 | Active |
| US10919927B2 | Immune stimulating macrolide | Emerging Cross-Sectional Technologies | 0 | Active |
| US12310940B2 | Cell-permeable succinate compounds | Emerging Cross-Sectional Technologies | 0 | Active |
| US11434258B2 | Compounds (immunorhelins) | Human Necessities | 0 | Active |
| US11059845B2 | Immune stimulating macrolides | Human Necessities | 0 | Active |
| US9976165B2 | Methods for increasing molecular diversity of polyketides and non-ribosomal proteins | Emerging Cross-Sectional Technologies | 0 | Active |
| US11147789B2 | Cell-permeable succinate compounds | Emerging Cross-Sectional Technologies | 0 | Active |
| US9504728B2 | Dosage form | Human Necessities | 0 | Active |
| US9605001B2 | Production of polyketides and other natural products | Chemistry; Metallurgy | 0 | Active |
| US9271977B2 | Sanglifehrin derivatives and methods for their production | Emerging Cross-Sectional Technologies | 0 | Active |
| US9139613B2 | Macrocyclic compounds and methods for their production | Chemistry; Metallurgy | 0 | Active |
| US11304990B2 | Use of known compounds—intracellular infections | Emerging Cross-Sectional Technologies | 0 | Active |
| US10857150B2 | Use of sanglifehrin macrocyclic analogues as anticancer compounds | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.